166 related articles for article (PubMed ID: 38009933)
1. Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone.
Kazi I; Chenoweth MJ; Jutras-Aswad D; Ahamad K; Socias ME; Le Foll B; Tyndale RF
Clin Pharmacol Ther; 2024 Mar; 115(3):506-514. PubMed ID: 38009933
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.
Crist RC; Li J; Doyle GA; Gilbert A; Dechairo BM; Berrettini WH
Am J Drug Alcohol Abuse; 2018; 44(4):431-440. PubMed ID: 29333880
[TBL] [Abstract][Full Text] [Related]
3. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
[TBL] [Abstract][Full Text] [Related]
4. A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence.
Crist RC; Doyle GA; Nelson EC; Degenhardt L; Martin NG; Montgomery GW; Saxon AJ; Ling W; Berrettini WH
Pharmacogenomics J; 2018 Jan; 18(1):173-179. PubMed ID: 27958381
[TBL] [Abstract][Full Text] [Related]
5. Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
Bakouni H; McAnulty C; Tatar O; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
Am J Addict; 2023 Sep; 32(5):469-478. PubMed ID: 37308805
[TBL] [Abstract][Full Text] [Related]
6. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
7. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
8. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
Sadek J; Saunders J
BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
[TBL] [Abstract][Full Text] [Related]
9. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
Bakouni H; Sharafi H; Drouin S; Fortin R; Marsan S; Brissette S; Socias ME; Le Foll B; Lim R; Jutras-Aswad D
Can J Psychiatry; 2024 Apr; 69(4):252-263. PubMed ID: 37899716
[TBL] [Abstract][Full Text] [Related]
10. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
Srivastava A; Kahan M; Nader M
Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
[TBL] [Abstract][Full Text] [Related]
11. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
[TBL] [Abstract][Full Text] [Related]
12. Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study.
Bakouni H; Haquet L; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
J Addict Med; 2024 Mar-Apr 01; 18(2):167-173. PubMed ID: 38258865
[TBL] [Abstract][Full Text] [Related]
13. Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
Saunders EC
Am J Psychiatry; 2022 Oct; 179(10):699-701. PubMed ID: 36181331
[No Abstract] [Full Text] [Related]
14. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
[TBL] [Abstract][Full Text] [Related]
15. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
Bishop B; Gilmour J; Deering D
Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
[TBL] [Abstract][Full Text] [Related]
16. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.
Crist RC; Clarke TK; Ang A; Ambrose-Lanci LM; Lohoff FW; Saxon AJ; Ling W; Hillhouse MP; Bruce RD; Woody G; Berrettini WH
Neuropsychopharmacology; 2013 Sep; 38(10):2003-10. PubMed ID: 23612435
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
Hser YI; Evans E; Huang D; Weiss R; Saxon A; Carroll KM; Woody G; Liu D; Wakim P; Matthews AG; Hatch-Maillette M; Jelstrom E; Wiest K; McLaughlin P; Ling W
Addiction; 2016 Apr; 111(4):695-705. PubMed ID: 26599131
[TBL] [Abstract][Full Text] [Related]
18. Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.
Socias ME; Wood E; Le Foll B; Lim R; Choi JC; Mok WY; Bruneau J; Rehm J; Wild TC; Bozinoff N; Hassan A; Jutras-Aswad D;
Addiction; 2022 Oct; 117(10):2662-2672. PubMed ID: 35712892
[TBL] [Abstract][Full Text] [Related]
19. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM
Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760
[TBL] [Abstract][Full Text] [Related]
20. Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.
Thakrar AP; Uritsky TJ; Christopher C; Winston A; Ronning K; Sigueza AL; Caputo A; McFadden R; Olenik JM; Perrone J; Delgado MK; Lowenstein M; Compton P
Addict Sci Clin Pract; 2023 Feb; 18(1):13. PubMed ID: 36829242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
